Citrus Therapeutics Files U.S. Patent for CTZ1™ Groundbreaking Therapy for Age-Related Macular Degeneration (AMD)

A novel vascular disruptive antioxidant agent for treating wet and dry AMD with potential synergy given concurrent therapies
RIVERSIDE, Calif. - Sept. 26, 2022 - PRLog -- RIVERSIDE, CA – Citrus Therapeutics, LLC, a manufacturer of innovative therapies and an early leader in novel multi-pharmacophore agents for AMD treatment, announces that the U.S. Patent Office has issued Patent Application No. 17/837,917 for the "Therapeutic Agent for Treatment of Age-Related Macular Degeneration" and for the registration of the trade name "CTZ1™", the first-of-its-kind vascular disruptive agent (VDA) for treating both wet and dry AMD.

CTZ1™ is a unique vascular disruptive agent for combating the oxidative damage encountered in macular degeneration. CTZ1™ combines an antioxidant carbazole moiety fused to a nicotine analog; this multi-pharmacophore combination mitigates oxidant damage experienced in AMD.  As a Vascular Disruptive Agent, CTZ1™ can stabilize and temper pathological angiogenic processes secondary to progressive AMD.

CTZ1™ is currently being developed with potential as a topical (i.e., eye drop solution) and local (i.e., intravitreal) therapy.

CTZ1 is a lead candidate for the treatment of neovascular age-related macular degeneration. To learn more about CTZ1™ as a therapeutic agent, visit our website here: citrustherapeutics.com or email salkayali@citrustherapeutics.com

CTZ1™ debuts from Citrus Therapeutics, LLC, based in Riverside, California. Citrus Therapeutics is owned and operated by Eric Chin MD, David Almeida MD MBA PhD, and Mr. Ahmad Alkayali, inventor.  Citrus Therapeutics, LLC was formed to develop, research, and promote innovative multi-pharmacophore therapies.

David RP Almeida, MD MBA PhD, is a Board-Certified Ophthalmologist and Vitreoretinal Surgeon. Dr. Almeida is involved in diagnosing and treating conditions of the vitreous, retina, and macula. Dr. Almeida is Director of Clinical Research at Erie Retina Research and Medical Director for Ophthalmology Research at The Clinical Trials Network. Dr. Almeida is Chief Medical Editor of the online publication Eyes on Eyecare, ophthalmology division.

Eric K. Chin, M.D., Board-Certified ophthalmologist, is a graduate of the University of California Berkeley and Chicago Medical School. Dr. Chin was awarded several accolades for teaching and research on treatments for various retinal diseases. Dr. Chin is a partner at Retina Consultants of Southern California and serves as Clinical Faculty at Loma Linda University and Loma Linda Veterans Affairs Hospital.

Mr. Ahmad Alkayali is a renowned and trusted leader in developing and manufacturing natural ingredients for foods, beverages, and supplements. Mr. Alkayali is the original inventor of three Collagen Type II patents for dietary supplements and the first to introduce Collagen Types I, II, and III food supplements to the Health Food Industry more than 35 years ago. Mr. Alkayali's inventions and elements are incorporated into nutritional products that are recognized globally for cardiovascular, joint, skin, anti-aging, and eye health.

Contact
dalmeida@citrustherapeutics.com
***@citrustherapeutics.com
End
Email:***@citrustherapeutics.com Email Verified
Tags:AMD therapies, eye diseases
Industry:Health
Location:Riverside - California - United States
Subject:Products
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse



Like PRLog?
9K2K1K
Click to Share